Clinical Trial Update: Levodopa Concentration Profile With Stalevo 75/125 mg [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the concentration profile of Stalevo 75/125 mg (levodopa/carbidopa/entacapone) in Parkinson's disease; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Stalevo 75/125 mg (levodopa/carbidopa/entacapone)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED